<unk>  is a human anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab. The CD20 antigen is expressed on solely B cell lymphocytes. Compared with rituximab,<unk>  binds more tightly to CD20 with a slower off-rate. It causes cytotoxicity in the cells that express CD20 by means of complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Ofatumumab
Daratumumab
Alirocumab
Lanadelumab
Acalabrutinib
Tralokinumab
Sacituzumab govitecan
Bezlotoxumab